首页> Clinical cancer research : an official journal of the American Association for Cancer Research> A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.

导出 OA

翻译打印收藏纠错

第一作者： Jeffrey R,Infante

第一单位： Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee. jinfante@tnonc.com.

作者： Jeffrey R,Infante ^[1] ; Philippe A,Cassier ^[2] ; John F,Gerecitano ^[3] ; Petronella O,Witteveen ^[4] ; Rashmi,Chugh ^[5] ; Vincent,Ribrag ^[6] ; Abhijit,Chakraborty ^[7] ; Alessandro,Matano ^[8] ; Jason R,Dobson ^[7] ; Adam S,Crystal ^[7] ; Sudha,Parasuraman ^[7] ; Geoffrey I,Shapiro ^[9]

作者单位： Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee. jinfante@tnonc.com. ^[1] Centre Léon Bérard, Lyon, France. ^[2] Memorial Sloan Kettering Cancer Center, New York, New York. ^[3] University Medical Center Utrecht Cancer Center, Utrecht, the Netherlands. ^[4] University of Michigan, Ann Arbor, Michigan. ^[5] Institut Gustave Roussy, Villejuif, France. ^[6] Novartis Institutes for BioMedical Research, Cambridge, Massachusetts. ^[7] Novartis Pharma AG, Basel, Switzerland. ^[8] Dana-Farber Cancer Institute, Boston, Massachusetts. ^[9]